The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.00
Bid: 1.75
Ask: 2.25
Change: -1.50 (-42.86%)
Spread: 0.50 (28.571%)
Open: 1.875
High: 2.25
Low: 1.75
Prev. Close: 3.50
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Genedrive shares jump on orders

Wed, 20th Dec 2023 11:07

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Genedrive PLC, up 22% at 9.79 pence, 12-month range 5p-48.86p. The molecular diagnostics company receives initial orders of its MT-RNR1 hearing loss gene screening products from France, Austria, Greece, Saudi Arabia, Turkey and the Netherlands. Says the orders will support its international distribution partners in promoting and evaluating activities. "We look forward to the continued expansion of our international sales throughout 2024 as we drive forward with our sales and marketing strategies and deliver value to our shareholders," says CEO James Cheek.

----------

Angus Energy PLC, up 21% at 0.58p, 12-month range 0.45p-2p. The UK-focused onshore oil and gas developer agrees a GBP20 million debt facility with Trafigura PTE Ltd to refinance all its existing debt, as well as to fund additional capital expenditure projects to raise production at Saltfleetby field. Trafigura expects a closing date in the first month of 2024. Angus adds that its existing hedge contract will be replaced with a fixed price offtake, with Trafigura acting as offtaker. Says the new funds will accelerate work on gas storage feasibility.

----------

AIM - LOSERS

----------

Versarien PLC, down 52% at 0.15p, 12-month range 0.15p-10.16p. The advanced materials engineering group's stock hits an all-time low, as the firm updates the market on various developments. Says asset sales, which are "an integral part of its turnaround strategy", have not progressed as expected, and guides for a weaker performance in the year ended September 30, than the 18-month period prior to that. Says it has sufficient confidence in its business pipeline to launch an equity raise, but notes it is unable to issue subscription shares below its nominal price of 0.1p under UK company law. It will look to secure funding above the nominal value. However, to facilitate "flexibility" in its funding options, the firm proposes a capital reorganisation to sub-divide each share into one new ordinary share of 0.1p nominal value, and one new deferred share of 0.09p. Shareholders will be able to vote on the proposals at a general meeting on January 10.

----------

By Elizabeth Winter, Alliance News deputy news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
20 Apr 2020 11:40

Genedrive To Collaborate On Rapidly Manufactured Covid-19 Test

Genedrive To Collaborate On Rapidly Manufactured Covid-19 Test

Read more
25 Mar 2020 14:57

Genedrive Shares Soar As It Says It Will Develop SARS-COV-2 Tests

Genedrive Shares Soar As It Says It Will Develop SARS-COV-2 Tests

Read more
4 Feb 2020 12:22

Genedrive Shares Plunge 45% As Loss Widens On Shipping Order Delays

Genedrive Shares Plunge 45% As Loss Widens On Shipping Order Delays

Read more
28 Jan 2020 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
3 Dec 2019 10:10

Genedrive Antibiotic Induced Hearing Loss Test Kit Shows High Accuracy

Genedrive Antibiotic Induced Hearing Loss Test Kit Shows High Accuracy

Read more
3 Dec 2019 09:39

Genedrive upbeat on latest results from RNR1 kit testing

(Sharecast News) - Near-patient molecular diagnostics company Genedrive announced on Tuesday that in its case-control clinical validation, the antibiotic-induced hearing loss assay - the 'Genedrive MT-RNR1 ID' kit - achieved a diagnostic sensitivity of 100% and specificity of 100% on a cohort of 303 samples.

Read more
18 Nov 2019 16:00

Genedrive infant hearing loss test gets CE mark

(Sharecast News) - Molecular diagnostics company Genedrive announced on Monday that its antibiotic-induced hearing loss test, the 'Genedrive MT-RNR1 ID' kit, has obtained CE marking.

Read more
18 Nov 2019 11:15

Genedrive's Antibiotic Induced Hearing Loss Assay Receives CE Marking

Genedrive's Antibiotic Induced Hearing Loss Assay Receives CE Marking

Read more
7 Oct 2019 11:59

NHS Ethics Approval Granted For Genedrive MT-RNR1 Screening Test Trial

NHS Ethics Approval Granted For Genedrive MT-RNR1 Screening Test Trial

Read more
3 Oct 2019 11:00

Genedrive Outlook Positive As Revenue Up And Loss Narrows In Full Year

Genedrive Outlook Positive As Revenue Up And Loss Narrows In Full Year

Read more
3 Oct 2019 10:41

Genedrive loss narrowed after double-digit revenue rise

(Sharecast News) - Genedrive on Thursday reported a narrowed annual loss as revenues jumped as its commercial relationship with the US department of defense (DoD) exceeded expectations.

Read more
9 Jul 2019 10:54

Genedrive Revenue To Suffer On Lower Uptake Of Hepatitis Test Kits

(Alliance News) - Shares in Genedrive PLC fell Tuesday after the company warned that it will miss market expectations for 2020 financial year revenue due to slower than expected uptake of the HCV

Read more
28 Mar 2019 10:36

Genedrive Interim Loss Narrows As It Continues Focus On Hepatitis

LONDON (Alliance News) - Genedrive PLC on Thursday reported a reduction in its interim loss, as it continues to progress its hepatitis testing product.For the six months to the end of 2018,

Read more
28 Mar 2019 07:59

Genedrive losses narrow despite increased R&D costs

(Sharecast News) - Molecular diagnostics company Genedrive saw revenues tick ahead slightly in the first half of its financial year but increased research and development costs kept the firm in the red.

Read more
15 Jan 2019 12:44

Genedrive Interim Revenue Rises On US And UK Government Contracts

LONDON (Alliance News) - Genedrive PLC said Tuesday it increased its first-half income and made "good progress" on two UK government funded projects.For the six months to the end

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.